Responses

Download PDFPDF

A trial of recombinant human granulocyte colony stimulating factor for the treatment of very low birthweight infants with presumed sepsis and neutropenia
Free
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

PLEASE NOTE:

  • Responses are moderated before posting and publication is at the absolute discretion of BMJ, however they are not peer-reviewed
  • Once published, you will not have the right to remove or edit your response. Removal or editing of responses is at BMJ's absolute discretion
  • If patients could recognise themselves, or anyone else could recognise a patient from your description, please obtain the patient's written consent to publication and send them to the editorial office before submitting your response [Patient consent forms]
  • By submitting this response you are agreeing to our full [Response terms and requirements]

Vertical Tabs

Other responses

  • Published on:
    Use of rhG-CSF for VLBW babies with presumed sepsis and neutropoenia
    • Girish Gupta, Medical teacher
    • Other Contributors:
      • Venkatnarayan K, Wilson CG, Nair MNG

    Dear Editor

    We read with great enthusiasm the article on use of rhG-CSF for treatment of sepsis in VLBW by Bedford et al.[1] It emphasises the previous studies on the subject of potential use of rhG-CSF in management of neonatal sepsis, especially given its fewer side effects and its significant effect on neutrophil counts.

    While it is true that VLBW neonates have low neutrophil counts and storage pool...

    Show More
    Conflict of Interest:
    None declared.
  • Published on:
    Re: Recombinant human granulocyte colony stimulating factor therapy in neonates

    Dear Editor,

    We thank Drs Jog and Patole for their extremely valid comments regarding our paper, which provide us with the opportunity to share the information requested. The complete dataset was omitted in the interests of brevity and summarised in the statement that there were no significant differences in maternal and peripartum characteristics between the two groups.

    Antenatal steroids were administe...

    Show More
    Conflict of Interest:
    None declared.
  • Published on:
    Recombinant human granulocyte colony stimulating factor therapy in neonates
    Dear Editor,

    We read with interest the article by Bedford Russell et al on the use of rhG-CSF in very low birth weight neonates with presumed sepsis in a prospective randomised, placebo controlled trial. [1] Considering that the safety (primary objective) and efficacy of rhG-CSF (secondary outcome) was evaluated by factors like worsening of respiratory distress syndrome or chronic lung disease (CLD), thrombocytopenia, ri...

    Show More
    Conflict of Interest:
    None declared.